Alnylam Pharmaceuticals

Alnylam has pioneered RNAi therapeutics, an innovative approach to gene silencing. We are driven by science and committed to developing transformational medicines for patients.

Source: https://www.alnylam.com

vutrisiranAmvuttra

transthyretin-directed small interfering RNA

Amvuttra (vutrisiran) is a small interfering RNA medicine from Alnylam that silences production of transthyretin. It treats the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, and in the United States also the cardiomyopathy of wild-type or hereditary transthyretin amyloidosis.

Vutrisiran is given by injection every three months. It is a small interfering RNA that switches off the liver's production of transthyretin, the prot

1 medicine explained